Press Releases
January 8th, 2026
Virometix AG Announces Positive Data from Phase 1 Trial of V-212, a Fully Synthetic, Serotype-Independent Vaccine Development Candidate for the Prevention of Pneumococcal Disease
> For more information, please download PDF release
November 13th, 2025
Virometix AG Announces Completion of $15 Million Financing Round to Advance Development of V-212 and Next-Generation Synthetic Vaccines.
> For more information, please download PDF release
September 29th, 2025
Virometix Announces Completion of Enrollment in Phase I Trial of V-212 — a Fully Synthetic, Serotype-Independent Vaccine Candidate Against Streptococcus Pneumoniae
> For more information, please download PDF release
September 2024
Dr. Christina Ackermann joins Board of Directors.
November 2022
Dr. Christian Brander joins Advisory Board.
October 24th, 2022
Dr. Michael Babokhov joins our team at LabCentral.
August 2022
S. pneumoniae vaccine program PoC achieved.
August 28th, 2022
European & International Peptide Symposium 2022.
August 25th, 2022
Peptide Therapeutics Forum 2022.
July 2022
Virometix strengthens its team.
June 2022
RSV PhI clinical trial successfully completed.
June 27th, 2022
International Oligonucleotides and Peptides Conference.
June 19th, 2022
International Symposium on Pneumococcal Diseases 2022.
May 2022
Bob van Gemen joins Board of Directors.
April 2022
Prof. Fernando Albericio joins Advisory Board.
January 2022
Collaboration with the University Children’s Hospital in Athens.
July 14th, 2021
Virometix Announces Publication of Key Non-Clinical Proof-of-Concept Data in Two High Quality Peer-Reviewed Journals.
> For more information, please download PDF release
January 7th, 2021
Virometix Broadens Senior Leadership Team with Three Key Appointments
> For more information, please download PDF release
September 17th, 2020
Virometix Announces Completion of Initial Vaccination of the First Dose Cohort in Phase 1 Study with V-306
> For more information, please download PDF release
July 16th, 2020
Virometix Announces Successful Closing of Series B Investment Round raising CHF 7.5 million
Axel Polack and Anna Sumeray elected Members of the Board of Directors
> For more information, please download PDF release
July 9th, 2020
Anergis and Virometix Announce Research Collaboration to Use Synthetic Virus-Like Particles for Ultra-Fast Allergy Immunotherapy
> For more information please download PDF release
March 12th, 2020
Virometix announces initiation of Phase 1 clinical trial with its V-306 vaccine candidate.
> For more information please download PDF release
February 1st, 2019
Virometix announces initiation of Phase 1 clinical trial with its V-306 vaccine candidate
Virometix at Scientific Conferences
36th EPS (European Peptide Symposium) & 12th IPS (International Peptide Symposium)
28 August-2 September 2022, Barcelona, Spain
A multi target, T-cell epitope peptide vaccine candidate against SARS-CoV-2 and related mutant variants
Javier Rodriguez, Oliver Rassek, Agaristi Lamprokostopoulou, Anna Sumeray, Lilli Stergiou
> For more information, please download PDF release
36th EPS (European Peptide Symposium) & 12th IPS (International Peptide Symposium)
28 August-2 September 2022, Barcelona, Spain
A peptide-based, serotype-independent vaccine against Streptococcus pneumoniae
Agaristi Lamprokostopoulou, Oliver Rassek, Javier Rodriguez, Vana Spoulou, Anna Sumeray, Lilli Stergiou
> For more information, please download PDF release
ESPID 2023 (European Society for Pediatric Infectious Diseases)
8-12 May 2023, Lisbon, Portugal
V-212, a peptide-based, serotype-independent vaccine candidate against Streptococcus pneumoniae
Agaristi Lamprokostopoulou, Oliver Rassek, Javier Rodriguez, Vasiliki Daikopoulou, Markus Heck, Anna Sumeray, Lilli Stergiou
> For more information, please download PDF release
World Vaccine Congress West Coast
28-30 November 2023, Santa Clara, California, U.S.
V-212, a novel peptide-based, serotype-independent vaccine candidate against Streptococcus pneumoniae
Agaristi Lamprokostopoulou, Vasiliki Daikopoulou, Javier Rodriguez, Oliver Rassek, Anna Sumeray, Marc Mansour, Lilli Stergiou
> For more information, please download PDF release
ISPPD-13 (International Society of Pneumonia and Pneumococcal Diseases)
17-20 March 2024, Cape Town, South Africa
V-212, a novel peptide-based, serotype-independent vaccine candidate against Streptococcus pneumoniae
Agaristi Lamprokostopoulou, Vasiliki Daikopoulou, Maria Kokkori, Evangelia Kourepini, Vana Spoulou, Oliver Rassek, Javier Rodriguez, Anna Sumeray, Lilli Stergiou
> For more information, please download PDF release
Peptide Therapeutics Forum 2024 (Swiss Chemical Society)
22-23 August 2024, Basel, Switzerland
Engineered Synthetic Virus-Like Particles and their use in antigen delivery
Javier Rodriguez Balboa, Agaristi Lamprokostopoulou, Maria Kokkori, Evangelia Kourepini, Markus Heck , Vasiliki Daikopoulou, Oliver Rassek, Marc Mansour, Lilli Stergiou
> For more information, please download PDF release
Grand Rounds 2024
9-11 September 2024, Nashville, Tennessee, U.S.
V-212, a novel peptide-based, serotype-independent vaccine candidate against Streptococcus pneumoniae
Agaristi Lamprokostopoulou, Maria Kokkori, Vasiliki Daikopoulou, Evangelia Kourepini, Javier Rodriguez, Oliver Rassek, Anna Sumeray, Lilli Stergiou
> For more information, please download PDF release
World Vaccine Congress Washington
30 March-2 April 2025, Washington D.C., U.S.
V-212, a novel peptide-based, serotype-independent vaccine candidate against Streptococcus pneumoniae
Agaristi Lamprokostopoulou, Maria Kokkori, Vasiliki Daikopoulou, Evangelia Kourepini, Javier Rodriguez, Oliver Rassek, Marc Mansour, Lilli Stergiou
Publications
Double-Blind, Placebo-Controlled, Dose-Escalating Study Evaluating the Safety and Immunogenicity of an Epitope-Specific Chemically Defined Nanoparticle RSV Vaccine.
Leroux-Roels I, Bruhwyler J, Stergiou L, Sumeray M, Joye J, Maes C, Lambert PH, Leroux-Roels G. Double-Blind, Placebo-Controlled, Dose-Escalating Study Evaluating the Safety and Immunogenicity of an Epitope-Specific Chemically Defined Nanoparticle RSV Vaccine. Vaccines (Basel). 2023 Feb 6;11(2):367. doi: 10.3390/vaccines11020367.
Epicutaneous immunization using synthetic virus-like particles efficiently boosts protective immunity to respiratory syncytial virus
Pierre-Louis Hervé, Véronique Dhelft, Armando Zuniga, Arin Ghasparian, Oliver Rassek, Kevin C. Yim, Nathalie Donne, Paul-Henri Lambert, Pierre-Henri Benhamou, Hugh A. Sampson, Lucie Mondoulet
https://doi.org/10.1016/j.vaccine.2021.03.081
An epitope-specific chemically defined nanoparticle vaccine for respiratory syncytial virus
Armando Zuniga, Oliver Rassek, Melissa Vrohlings, Aniebrys Marrero-Nodarse, Kerstin Moehle, John A. Robinson, Arin Ghasparian
npj Vaccines (2021) 6:85 ; https://doi.org/10.1038/s41541-021-00347-y
Synthetic virus-like particles from self-assembling coiled-coil lipopeptides and their use in antigen display to the immune system.
Boato F, Thomas RM, Ghasparian A, Freund-Renard A, Moehle K, Robinson JA.
Angew Chem Int Ed Engl. 2007;46(47):9015-8. doi: 10.1002/anie.200702805. PMID: 17935102 No abstract available.
Synthetic virus-like particles and conformationally constrained peptidomimetics in vaccine design.
Riedel T, Ghasparian A, Moehle K, Rusert P, Trkola A, Robinson JA
Chembiochem. 2011 Dec 16;12(18):2829-36. doi: 10.1002/cbic.201100586. Epub 2011 Nov 11. PMID: 22076829
Max Bergmann lecture protein epitope mimetics in the age of structural vaccinology.
Robinson JA
J Pept Sci. 2013 Mar;19(3):127-40. doi: 10.1002/psc.2482. Epub 2013 Jan 24. PMID: 23349031 Free PMC article. Review.
Engineered synthetic virus-like particles and their use in vaccine delivery.
Ghasparian A, Riedel T, Koomullil J, Moehle K, Gorba C, Svergun DI, Perriman AW, Mann S, Tamborrini M, Pluschke G, Robinson JA.
Chembiochem. 2011 Jan 3;12(1):100-9. doi: 10.1002/cbic.201000536. PMID: 21132689
Dendritic Cell Sensing of Hydrophobic Di- and Triacylated Lipopeptides Self-Assembled within Synthetic Virus-like Particles. R. Sharma et al. J Immunol. 2017 Jul 15;199(2):734-749.
> PubMed
A synthetic virus-like particle streptococcal vaccine candidate using B-cell epitopes from the proline-rich region of pneumococcal surface protein A. Tamborrini M. et al. Vaccines (Basel) 2015 Oct 16, 3, 850-874.
> PubMed
Ghasparian, A. and Robinson J.A. 2015, Synthetic Virus-like Particles in Vaccine Design. In Khudyakov Y. and Pumpens P. (Eds.), Viral Nanotechnology, p. 487–498 New York, CRC Press Book.
Functionalization of protein-based nanocages for drug delivery applications. Schoonen L et al. Nanoscale. 2014 Jul 7;6(13):7124-41.
> PubMed
Vaccines based on structure-based design provide protection against infectious diseases. Thomas S, Luxon BA. Expert Rev Vaccines. 2013 Nov;12(11):1301-11.
> PubMed
Applications of nanotechnology for immunology. Smith DM et al. Nat Rev Immunol. 2013 Aug;13(8):592-605.
> PubMed
Max Bergmann lecture protein epitope mimetics in the age of structural vaccinology. Robinson JA, J Pept Sci. 2013 Mar;19(3):127-40.
> PubMed
Virus-like particles as a highly efficient vaccine platform: diversity of targets and production systems and advances in clinical development. Kushnir N et al. Vaccine. 2012 Dec 17;31(1):58-83.
> PubMed
Synthetic virus-like particles target dendritic cell lipid rafts for rapid endocytosis primarily but not exclusively by macropinocytosis. Sharma R et al. PLoS One. 2012;7(8):e43248.
> PubMed
Synthetic virus-like particles and conformationally constrained peptidomimetics in vaccine design. Riedel T et al. Chembiochem. 2011 Dec 16;12(18):2829-36.
> PubMed
Materials from peptide assembly: towards the treatment of cancer and transmittable disease. Branco MC et al. Curr Opin Chem Biol. 2011 Jun; 15(3): 427-34.
> PubMed
Peptide-based subunit nanovaccines. Skwarczynski M, Toth I. Curr Drug Deliv. 2011 May; 8(3): 282-9.
> PubMed
Engineered synthetic virus-like particles and their use in vaccine delivery. Ghasparian A et al. Chembiochem. 2011 Jan 3; 12(1): 100-9.
> PubMed
Synthetic viruslike particles and hybrid constructs based on lipopeptide self-assembly. Perriman AW et al. Small. 2010 Jun 6;6(11):1191-6.
> PubMed
Synthetic virus-like particles from self-assembling coiled-coil lipopeptides and their use in antigen display to the immune system. Boato F, Thomas RM, Ghasparian A, Freund-Renard A, Moehle K, Robinson JA. Angew Chem Int Ed Engl.2007;46(47):9015-8.
> PubMed